The need for neuroprotective therapies in Parkinson's disease: a clinical perspective.
about
α-Synuclein genetic variants predict faster motor symptom progression in idiopathic Parkinson diseaseEnlarged hyperechogenic substantia nigra is related to motor performance and olfaction in the elderly.Neuroimaging: current role in detecting pre-motor Parkinson's disease.The PRIPS study: screening battery for subjects at risk for Parkinson's disease.Enlarged hyperechogenic substantia nigra as a risk marker for Parkinson's disease.The clinical symptoms of Parkinson's disease.Pramipexole for the treatment of early Parkinson's disease.Functional models of Parkinson's disease: a valuable tool in the development of novel therapies.Serum metabolomics of slow vs. rapid motor progression Parkinson's disease: a pilot study.Factors associated with exercise behavior in people with Parkinson disease.Promoting exercise in Parkinson's disease through community-based participatory research.Establishment of a survival and toxic cellular model for Parkinson's disease from chicken mesencephalon.Self-amplification of nigral degeneration in Parkinson's disease: a hypothesis.Pramipexole extended-release (once-daily formulation) for the treatment of Parkinson's disease.Defining meaningful outcome measures in trials of disease-modifying therapies in Parkinson's disease.Cell replacement therapy for Parkinson's disease: how close are we to the clinic?Emerging analgesic drugs for Parkinson's disease.An economic model of Parkinson's disease: implications for slowing progression in the United States.The prevalence and incidence of Parkinson's disease in China: a systematic review and meta-analysis.Parkinson's disease and risk of mortality: meta-analysis and systematic review.Preconditioning as a potential strategy for the prevention of Parkinson's disease.Assessment of disease progression and functional benefit in neurodegenerative disease: can we tell the difference?Systematic review of traditional chinese medicine for depression in Parkinson's disease.A cumulative genetic risk score predicts progression in Parkinson's disease.[Hip replacement in patients with neuromuscular disorders].Transcranial sonography of the substantia nigra: digital image analysis.Association of GBA Mutations and the E326K Polymorphism With Motor and Cognitive Progression in Parkinson Disease.Triptolide protects against 1-methyl-4-phenyl pyridinium-induced dopaminergic neurotoxicity in rats: implication for immunosuppressive therapy in Parkinson's disease.Why is there motor deterioration in Parkinson's disease during systemic infections-a hypothetical view.Controlling futures? Online Genetic Testing and Neurodegenerative Disease : Comment on "Personal Genomic Testing, Genetic Inheritance, and Uncertainty".Age-Dependence and Aging-Dependence: Neuronal Loss and Lifespan in a C. elegans Model of Parkinson's Disease.Statistical Models of Parkinson's Disease Progression: Predictive Validity in a 3-Year Follow-up.
P2860
Q21090919-DB9B34A6-6827-4EC8-B3F2-EFA8307F3629Q33632441-47AFE879-7B70-45E9-9AF5-5AAEB0756B7BQ34234625-CEC80DDB-C9F0-4039-9F10-B3579EF449C9Q34361343-E148711F-6D59-4F05-8B7A-E8CCEF99930EQ34463276-2D99B16A-910E-4A07-9D4D-99E8AE15BCFAQ34533843-755E40DF-CEFC-4D21-A48A-595C7D293A2EQ34630735-391E3FDB-5EF2-41BE-BBD6-DC941BFEED0DQ34916732-76411A4F-7766-4E40-8AED-E58EFE699EBBQ35027763-DB244C4C-A857-4C88-87A7-48FAD5B0D18FQ35587774-26E8EFAE-8F6A-4EB3-A178-4F39D264B63FQ35915858-8DE70FB5-8B36-41C6-AEE1-FAF25F09D976Q36952026-47A7692A-1607-474A-9CBB-1F7613261921Q37303959-E2E34E32-A9EE-4554-B220-6BB7451B2DF6Q37776519-8B0E2942-AB81-4089-AEF6-9A4EF644D2FAQ37846235-58074F7C-C287-453F-9172-383E6735BB70Q37921767-A08A6673-961D-4365-A5D6-9230C1D35793Q38005224-96961643-C58B-458D-8E5C-704605CDC595Q38081100-EB31645D-E1C7-4BF6-93AE-8946096CCE32Q38140733-E39CAFD8-F12B-4865-85F3-515DAD8B884CQ38164424-3151593D-3C3F-41B7-9257-B59778028907Q38201685-9D2A0A2D-2CB0-4438-826A-042EAF635714Q38219475-C87428DA-F66A-4DA4-991E-72F730155836Q38245667-2312ABC9-31E2-4E4B-A2D3-4944E48CE1B2Q38725615-9FAB54A6-FB14-4B58-9F9F-A93C48D491DAQ39187039-A83F0D6E-BC79-4865-8AFB-2602645668B6Q40210090-CA6E6233-F2D0-430C-AC63-8286AE073D7DQ40603461-DBDE149F-2E0A-441D-BD53-65A6A3AFCF51Q41351319-A140FD46-996D-477B-9FF0-BAC3B67DEFF3Q42334435-601AE128-292E-408D-A528-A3855044F916Q47590437-ACE4271D-EB31-4B5E-99F4-301F2CDDAEF6Q48320178-DDE478BD-64EA-4EA9-B604-2CE60F65587DQ50241406-8AA46719-F26E-43B3-BEBF-F6695695D373
P2860
The need for neuroprotective therapies in Parkinson's disease: a clinical perspective.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
The need for neuroprotective therapies in Parkinson's disease: a clinical perspective.
@en
type
label
The need for neuroprotective therapies in Parkinson's disease: a clinical perspective.
@en
prefLabel
The need for neuroprotective therapies in Parkinson's disease: a clinical perspective.
@en
P1433
P1476
The need for neuroprotective therapies in Parkinson's disease: a clinical perspective.
@en
P356
10.1212/WNL.66.10_SUPPL_4.S2
P407
P433
10 Suppl 4
P50
P577
2006-05-01T00:00:00Z